vs
Side-by-side financial comparison of CORCEPT THERAPEUTICS INC (CORT) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
CORCEPT THERAPEUTICS INC is the larger business by last-quarter revenue ($202.1M vs $196.9M, roughly 1.0× Pacira BioSciences, Inc.). On growth, CORCEPT THERAPEUTICS INC posted the faster year-over-year revenue change (11.1% vs 5.1%). Pacira BioSciences, Inc. produced more free cash flow last quarter ($43.5M vs $38.4M). Over the past eight quarters, CORCEPT THERAPEUTICS INC's revenue compounded faster (17.3% CAGR vs 8.5%).
Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
CORT vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $202.1M | $196.9M |
| Net Profit | $24.3M | — |
| Gross Margin | 98.7% | 79.5% |
| Operating Margin | 2.2% | 1.2% |
| Net Margin | 12.0% | — |
| Revenue YoY | 11.1% | 5.1% |
| Net Profit YoY | -21.0% | — |
| EPS (diluted) | $0.20 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $202.1M | $196.9M | ||
| Q3 25 | $207.6M | $179.5M | ||
| Q2 25 | $194.4M | $181.1M | ||
| Q1 25 | $157.2M | $168.9M | ||
| Q4 24 | $181.9M | $187.3M | ||
| Q3 24 | $182.5M | $168.6M | ||
| Q2 24 | $163.8M | $178.0M | ||
| Q1 24 | $146.8M | $167.1M |
| Q4 25 | $24.3M | — | ||
| Q3 25 | $19.7M | $5.4M | ||
| Q2 25 | $35.1M | $-4.8M | ||
| Q1 25 | $20.5M | $4.8M | ||
| Q4 24 | $30.7M | — | ||
| Q3 24 | $47.2M | $-143.5M | ||
| Q2 24 | $35.5M | $18.9M | ||
| Q1 24 | $27.8M | $9.0M |
| Q4 25 | 98.7% | 79.5% | ||
| Q3 25 | 97.8% | 80.9% | ||
| Q2 25 | 98.2% | 77.4% | ||
| Q1 25 | 98.5% | 79.7% | ||
| Q4 24 | 98.4% | 78.7% | ||
| Q3 24 | 98.4% | 76.9% | ||
| Q2 24 | 98.5% | 75.1% | ||
| Q1 24 | 98.3% | 71.6% |
| Q4 25 | 2.2% | 1.2% | ||
| Q3 25 | 4.9% | 3.5% | ||
| Q2 25 | 13.7% | 4.7% | ||
| Q1 25 | 2.2% | 1.2% | ||
| Q4 24 | 13.9% | 13.2% | ||
| Q3 24 | 25.5% | -82.8% | ||
| Q2 24 | 21.7% | 15.9% | ||
| Q1 24 | 20.1% | 7.9% |
| Q4 25 | 12.0% | — | ||
| Q3 25 | 9.5% | 3.0% | ||
| Q2 25 | 18.1% | -2.7% | ||
| Q1 25 | 13.1% | 2.8% | ||
| Q4 24 | 16.9% | — | ||
| Q3 24 | 25.9% | -85.1% | ||
| Q2 24 | 21.7% | 10.6% | ||
| Q1 24 | 18.9% | 5.4% |
| Q4 25 | $0.20 | $0.05 | ||
| Q3 25 | $0.16 | $0.12 | ||
| Q2 25 | $0.29 | $-0.11 | ||
| Q1 25 | $0.17 | $0.10 | ||
| Q4 24 | $0.25 | $0.38 | ||
| Q3 24 | $0.41 | $-3.11 | ||
| Q2 24 | $0.32 | $0.39 | ||
| Q1 24 | $0.25 | $0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $372.2M | $238.4M |
| Total DebtLower is stronger | — | $372.2M |
| Stockholders' EquityBook value | $647.8M | $693.1M |
| Total Assets | $836.7M | $1.3B |
| Debt / EquityLower = less leverage | — | 0.54× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $372.2M | $238.4M | ||
| Q3 25 | $421.7M | $246.3M | ||
| Q2 25 | $342.2M | $445.9M | ||
| Q1 25 | $322.8M | $493.6M | ||
| Q4 24 | $383.3M | $484.6M | ||
| Q3 24 | $380.3M | $453.8M | ||
| Q2 24 | $473.2M | $404.2M | ||
| Q1 24 | $410.8M | $325.9M |
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $647.8M | $693.1M | ||
| Q3 25 | $631.9M | $727.2M | ||
| Q2 25 | $635.8M | $757.8M | ||
| Q1 25 | $683.3M | $798.5M | ||
| Q4 24 | $679.6M | $778.3M | ||
| Q3 24 | $638.8M | $749.6M | ||
| Q2 24 | $596.2M | $879.3M | ||
| Q1 24 | $547.9M | $892.2M |
| Q4 25 | $836.7M | $1.3B | ||
| Q3 25 | $823.6M | $1.3B | ||
| Q2 25 | $801.7M | $1.5B | ||
| Q1 25 | $846.5M | $1.6B | ||
| Q4 24 | $840.6M | $1.6B | ||
| Q3 24 | $784.3M | $1.5B | ||
| Q2 24 | $714.6M | $1.6B | ||
| Q1 24 | $655.9M | $1.6B |
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $38.4M | $43.7M |
| Free Cash FlowOCF − Capex | $38.4M | $43.5M |
| FCF MarginFCF / Revenue | 19.0% | 22.1% |
| Capex IntensityCapex / Revenue | 0.0% | 0.1% |
| Cash ConversionOCF / Net Profit | 1.58× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $136.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $38.4M | $43.7M | ||
| Q3 25 | $54.5M | $60.8M | ||
| Q2 25 | $43.9M | $12.0M | ||
| Q1 25 | $5.1M | $35.5M | ||
| Q4 24 | $59.3M | $33.1M | ||
| Q3 24 | $73.8M | $53.9M | ||
| Q2 24 | $41.2M | $53.2M | ||
| Q1 24 | $23.8M | $49.1M |
| Q4 25 | $38.4M | $43.5M | ||
| Q3 25 | — | $57.0M | ||
| Q2 25 | $43.9M | $9.3M | ||
| Q1 25 | $5.0M | $26.9M | ||
| Q4 24 | $59.2M | $31.0M | ||
| Q3 24 | $72.2M | $49.8M | ||
| Q2 24 | $40.8M | $51.6M | ||
| Q1 24 | — | $46.3M |
| Q4 25 | 19.0% | 22.1% | ||
| Q3 25 | — | 31.7% | ||
| Q2 25 | 22.6% | 5.1% | ||
| Q1 25 | 3.2% | 15.9% | ||
| Q4 24 | 32.5% | 16.6% | ||
| Q3 24 | 39.5% | 29.6% | ||
| Q2 24 | 24.9% | 29.0% | ||
| Q1 24 | — | 27.7% |
| Q4 25 | 0.0% | 0.1% | ||
| Q3 25 | 0.0% | 2.2% | ||
| Q2 25 | 0.0% | 1.5% | ||
| Q1 25 | 0.1% | 5.1% | ||
| Q4 24 | 0.1% | 1.1% | ||
| Q3 24 | 0.9% | 2.4% | ||
| Q2 24 | 0.3% | 0.9% | ||
| Q1 24 | 0.0% | 1.7% |
| Q4 25 | 1.58× | — | ||
| Q3 25 | 2.77× | 11.20× | ||
| Q2 25 | 1.25× | — | ||
| Q1 25 | 0.25× | 7.37× | ||
| Q4 24 | 1.93× | — | ||
| Q3 24 | 1.56× | — | ||
| Q2 24 | 1.16× | 2.82× | ||
| Q1 24 | 0.86× | 5.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CORT
Segment breakdown not available.
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
